Home Pipeline

Overview

MacroGenics has a diverse portfolio of oncology product candidates with several clinical trials currently underway or planned for the near future. Set forth below is the company’s development pipeline of product candidates for which we have retained commercialization or other important rights in the U.S. or more broadly (as of Feb. 24, 2022).

In addition to the molecules identified below, MacroGenics has out-licensed various other clinical-stage product candidates for which it retains certain economic rights. These include retifanlimab and teplizumab.
 

Program (Target) Potential Indication(s) First-in-Human (Phase 1) Proof-of-Concept
(Phase 2)
Pivotal
(Phase 3)
Major Market Rights
MGC018
(B7-H3)
mCRPC, NSCLC, SCCHN, Melanoma
placeholder
 
Multiple Solid Tumors
(+lorigerlimab)
placeholder
 
 
Enoblituzumab
(B7-H3)
SCCHN (Head & Neck Cancer) (+retifanlimab/tebotelimab)
placeholder
  Greater China
 
Lorigerlimab
(PD-1 × CTLA-4)
MSS CRC, NSCLC, mCRPC, Melanoma
placeholder
   
 
Tebotelimab
(PD-1 × LAG-3)
Solid Tumors & Heme Malignancies
placeholder
  Greater China
 
IMGC936
(ADAM9)
NSCLC, Gastric, Pancreatic, TNBC and Other Solid Tumors
placeholder
  50/50
 
MGD024
(CD123 × CD3)
CD123+ Heme Malignancies
placeholder
Plan to initiate in 2022a
   

Oncology
MGC018 (B7-H3)
mCRPC, NSCLC, SCCHN, Melanoma
Phase 1 Phase 2 Phase3
placeholder
Multiple Solid Tumors (+lorigerlimab)
Phase 1 Phase 2 Phase3
placeholder
Major Market Rights: 

 
SCCHN (Head & Neck Cancer) (+retifanlimab/tebotelimab)
Phase 1 Phase 2 Phase3
placeholder
Major Market Rights: 

Greater China
 
Lorigerlimab
(PD-1 × CTLA-4)
MSS CRC, NSCLC, mCRPC, Melanoma
Phase 1 Phase 2 Phase3
placeholder
Major Market Rights: 

 
Tebotelimab
(PD-1 × LAG-3)
Solid Tumors & Heme Malignancies
Phase 1 Phase 2 Phase3
placeholder
Major Market Rights: 

Greater China
 
IMGC936
(ADAM9)
NSCLC, Gastric, Pancreatic, TNBC and Other Solid Tumors
Phase 1 Phase 2 Phase3
placeholder
Major Market Rights: 

50/50
 
MGD024
(CD123 × CD3)
CD123+ Heme Malignancies
Phase 1 Phase 2 Phase3
placeholder

Plan to initiate in 2022a

Major Market Rights: 

 
MGD = DART MGA = AntibodyMGC = ADC

The safety and efficacy of investigational agents and/or investigational uses of approved products have not been established.
 

Please note – you will leave a website owned by MacroGenics, Inc.

MacroGenics is not responsible for any content on the third party website.

Ok Close